Interleukin 22 signaling promotes cell growth in mantle cell lymphoma

Translational Oncology

Volumn 4, Issue 1, 2011, Pages 9-19

  Gelebart, Pascal ^a   Zak, Zoulika ^a   Dien Bard, Jennifer ^a   Anand, Mona ^a   Lai, Raymond ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 22; STAT3 PROTEIN;

ARTICLE; CELL GROWTH; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 79251578072     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10172     Document Type: Article

References (56)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, and Vardiman JW (2008). Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. WHO Classification of Tumours, Volume 2. WHO, Geneva, Switzerland. pp. 229-232.
2. Ghielmini M and Zucca E (2009). How I treat mantle cell lymphoma. Blood 114, 1469-1476.
3. Gill S and Ritchie D (2008). Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 49(3), 398-409.
4. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, et al. (2009). Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4),511-518.
5. Smith MR (2008). Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 15(4), 415-421.
6. Gladden AB and Diehl JA (2005). Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96(5), 906-913.
7. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, Fend F, and Quintanilla-Martinez L (2008). Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22(11), 2097-2105.
8. Vater I, Wagner F, Kreuz M, Berger H, Martin-Subero JI, Pott C, Martinez-Climent JA, Klapper W, Krause K, Dyer MJ, et al. (2009). GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 144(3), 317-331.
9. Kawamata N, Ogawa S, Gueller S, Ross SH, Huynh T, Chen J, Chang A, Nabavi-Nouis S, Megrabian N, Siebert R, et al. (2009). Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 37(8), 937-946.
10. Schraders M, Jares P, Bea S, Schoenmakers EF, van Krieken JH, Campo E, and Groenen PJ (2008). Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. Br J Haematol 143(2), 210-221.
11. Cecconi D, Zamo A, Bianchi E, Parisi A, Barbi S, Milli A, Rinalducci S, Rosenwald A, Hartmann E, Zolla L, et al. (2008). Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 8(21), 4495-4506.
12. Henrickson SE, Hartmann EM, Ott G, and Rosenwald A (2007). Gene expression profiling in malignant lymphomas. Adv Exp Med Biol 593, 134-146.
13. Camps J, Salaverria I, Garcia MJ, Prat E, Bea S, Pole JC, Hernandez L, Del Rey J, Cigudosa JC, Bernues M, et al. (2006). Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 30(8), 923-934.
14. Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK, and Zago MA (2005). Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 130(4), 516-526.
15. Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, et al. (2005). Pro-teomic analysis of mantle-cell lymphoma by protein microarray. Blood 105(9), 3722-3730.
16. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM, and Lai R (2008). Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 112(13), 5171-5179.
17. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, and McDonnell TJ (2003). Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol 199(1), 84-89.
18. Dumoutier L, Louahed J, and Renauld JC (2000). Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164(4), 1814-1819.
19. Dumoutier L, Van Roost E, Ameye G, Michaux L, and Renauld JC (2000). IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 1(8), 488-494.
20. Commins S, Steinke JW, and Borish L (2008). The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 121(5), 1108-1111.
21. Chung Y, Yang X, Chang SH, Ma L, Tian Q, and Dong C (2006). Expression and regulation of IL-22 in the IL-17-producing CD4 T lymphocytes. CellRes 16(11), 902-907.
22. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, and Fouser LA (2006). Interleukin (IL)-22 and IL-17 are coexpressed by Th1 7 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10), 2271-2279.
23. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM, Mills JC, and Colonna M (2009). A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457(7230), 722-725.
24. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, Bergman R, Krueger JG, and Guttman-Yassky E (2009). IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing Th17 T cells. J Allergy Clin Immunol 123(6), 1244-1252, e1242.
25. Ricciardi L, Minciullo PL, Saitta S, Trombetta D, Saija A, and Gangemi S (2009). Increased serum levels of IL-22 in patients with nickel contact dermatitis. Contact Dermatitis 60(1), 57-58.
26. Vivier E, Spits H, and Cupedo T (2009). Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol 9(4), 229-234.
27. Trifari S, Kaplan CD, Tran EH, Crellin NK, and Spits H (2009). Identification of a human helper T cell population that has abundant production of interleu-kin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10(8), 864-871.
28. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, and Gurney AL (2000). Interleukin (IL)-22, a novel human cy-tokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 275(40), 31335-31339.
29. Bleicher L, de Moura PR, Watanabe L, Colau D, Dumoutier L, Renauld JC, and Polikarpov I (2008). Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism. FEBS Lett 582(20), 2985-2992.
30. de Oliveira Neto M, Ferreira JR Jr, Colau D, Fischer H, Nascimento AS, Craievich AF, Dumoutier L, Renauld JC, and Polikarpov I (2008). Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J 94(5), 1754-1765.
31. Jones BC, Logsdon NJ, and Walter MR (2008). Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 16(9), 1333-1344.
32. Shioya M, Andoh A, Kakinoki S, Nishida A, and Fujiyama Y (2008). Interleu-kin 22 receptor 1 expression in pancreas islets. Pancreas 36(2), 197-199.
33. Ramanathan M Jr, Spannhake EW, and Lane AP (2007). Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor. Laryngoscope 117(10), 1839-1843.
34. Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prufer T, Olszak T, Steib CJ, Storr M, et al. (2007). IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 292(4), G1019-G1028.
35. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, and de Waal Malefyt R (2004). Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4(5), 679-691.
36. Lecart S, Morel F, Noraz N, Pene J, Garcia M, Boniface K, Lecron JC, and Yssel H (2002). IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 14(11), 1351-1356.
37. Ratsep R, Kingo K, Karelson M, Reimann E, Raud K, Silm H, Vasar E, and Koks S (2008). Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol 159(6), 1275-1281.
38. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, et al. (2009). STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206(7), 1465-1472.
39. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, and Tian Z (2008). Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14(20), 6432-6439.
40. Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, and Muhl H (2007). The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282(22), 16006-16015.
41. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, and Essler M (2006). IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177(11), 8266-8272.
42. Bard JD, Gelebart P, Anand M, Amin HM, and Lai R (2008). Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumor-igenecity in ALK+ anaplastic large cell lymphoma. Leukemia 22, 1595-1603.
43. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, and Lai R (2003). Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 127(4), 424-431.
44. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, and Pestka S (2001). Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276(4), 2725-2732.
45. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, and Renauld JC (2002). Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277(37), 33676-33682.
46. Shishodia S, Amin HM, Lai R, and Aggarwal BB (2005). Curcumin (diferuloyl-methane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70(5), 700-713.
47. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, and Colomer D (2007). Selective inhibition of IkappaB kinase sensitizes mantle cell lym-phoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 178(3), 1923-1930.
48. 2+ entry enhances muscarinic receptor- mediated soluble amyloid precursor protein (sAPPalpha) release in SH-SY5Y cells. J Biol Chem 281(18), 12722-12728.
49. Curry CL, Reed LL, Broude E, Golde TE, Miele L, and Foreman KE (2007). Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling. Mol Cancer Ther 6(7), 1983-1992.
50. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, and Hayashi H (2003). A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives. Bioorg Med Chem 11(18), 3869-3878.
51. Yang RH, Strong JA, and Zhang JM (2009). NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. Mol Pain 5, 26.
52. Armstrong SJ, Wiberg M, Terenghi G, and Kingham PJ (2008). Laminin activates NF-kappaB in Schwann cells to enhance neurite outgrowth. Neurosci Lett 439(1), 42-46.
53. Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM, and Jagt DL (2006). Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha- induced activation of transcription factor nuclear factor kappaB. J Med Chem 49(24), 7182-7189.
54. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, et al. (2006). IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290(4), G827-G838.
55. Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Tang XW, Li WX, Li LH, et al. (2009). Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta 401(1-2), 179-180.
56. Cheng F, Guo Z, Xu H, Yan D, and Li Q (2009). Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 68(4), 604-606.